WHO sees ‘great news’ in steroid’s trial results in COVID-19 By Reuters

© Reuters. FILE PHOTO: A logo is pictured on the World Health Organization headquarters in Geneva

(Reuters) – The World Health Organization (WHO) hailed as “great news” initial clinical trial results that showed a cheap and widely used steroid called dexamethasone can help save the lives of critically ill COVID-19 patients.

“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” WHO Director-General Tedros Adhanom Ghebreyesus said in a statement late on Tuesday.

“This is great news and I congratulate the government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough.”

The researchers shared initial insights about the results of the trial with WHO, “and we are looking forward to the full data analysis in the coming days,” it said.

“WHO will coordinate a meta-analysis to increase our overall understanding of this intervention. WHO clinical guidance will be updated to reflect how and when the drug should be used in COVID-19,” the agency added.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

You may also like...